News & Videos - PAINREFORM

TEL AVIV, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful closing of its previously announced acquisition of 100% of the business activity of DeepSolar, an AI-driven solar analytics platform, from BladeRanger Ltd, a public company registered under the laws of the State of Israel, whose shares are...

DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of...

TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. PainReform previously disclosed initial topline data from its Phase 3 clinical trial in which it reported that it...

TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research ("Lotus"), for the Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. Initial analysis...

This notification has no immediate effect on the listing or trading of PainReform’s ordinary shares on the Nasdaq Capital Market TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has received a notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”)...

TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive findings regarding the compatibility of sutures in human clinical trials of its lead product, PRF-110. PRF-110 is designed to provide extended, non-opiate, post-surgical pain relief. The Company conducted comprehensive in vitro studies to assess...

TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 989,300 ordinary shares of the Company originally issued in December 2023 and April 2024, having an exercise price of $4.80 per...

PRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds Findings Highlight PRF-110’s Competitive Edge Over Leading Pain Management Products TEL AVIV, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful determination of the optimal delivery method for PRF-110 in bunionectomy...

TEL AVIV, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced encouraging early safety results from its ongoing Phase 3 bunionectomy study of PRF-110, the Company’s proprietary post-surgical pain formulation. The study, which has now completed full enrollment with a total of 443 patients across eight clinical sites...

Reaches full enrollment in the second part of Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in late 2024 New highly scalable manufacturing process expected to significantly enhance future commercialization efforts TEL AVIV, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today...

TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces the successful development and manufacturing of new patented formulations of its extended postoperative pain relief therapy, PRF-110. These novel formulations may incorporate both the analgesic and an anti-inflammatory agent, designed to enhance postoperative...

TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced compelling safety data for its lead product candidate, PRF-110. This data, derived from pharmacokinetic (PK) studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110's promising safety profile, with maximum blood levels (Cmax)...

PRF-110 promoted normal wound healing and prevented scar formation following surgical procedures Company reaffirms it is on track to report top-line results from the Phase 3 trial in the second half of 2024 TEL AVIV, Israel, Aug. 05, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces positive wound healing data from its human clinical...

TEL AVIV, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces a major advancement in the development of its lead asset, PRF-110. The Company's new highly scalable manufacturing process, for which it recently filed a new patent, has enabled PRF-110 to achieve full product stability for 18 months at room temperature. This...

TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it has filed a patent covering its new and highly scalable manufacturing process for PRF-110, its flagship product designed to revolutionize post-operative pain control. The patent filing follows successful completion and testing of the new process. This...

TEL AVIV, Israel, June 26, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced a major milestone on the way to registration - the successful completion of patient enrollment in its Phase 3 clinical trial for PRF-110, a novel analgesic drug candidate designed for the treatment of post-operative pain. In total, 428 patients have been...

TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the “Letter”), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires...

Reaches 50% e nrollment in the s econd p art of its Phase 3 c linical t rial of PRF-110 in b unionectomy Remains on track to announce top-line data i n Q 3 202 4 TEL AVIV, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter ended March 31, 2024. Ilan Hadar, Chief Executive...

TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, participated in an interview with Proactiveinvestors.com. During the interview, Mr. Hadar discussed the advantages of PRF-110 to help tackle the opioid epidemic, including its ability to provide...

TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the closing of its previously announced public offering of an aggregate of 5,000,000 of the Company’s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 5,000,000 ordinary shares at a combined public offering price of...